New appointment at Merck & Co
This article was originally published in Scrip
Merck & Co has named Dr Michael Mendelsohn senior vice-president of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. He joins the company after 17 years at Tufts Medical Center in Boston. He was the founder and for twelve years the executive director of the Center's Molecular Cardiology Research Institute, and for the past two years served as the first chief scientific officer at Tufts. Dr Mendelsohn will be based at Merck's site in Rahway, New Jersey, and will report to the company's senior vice-president, global scientific strategy, Dr Luciano Rossetti.
You may also be interested in...
The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.
Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.
Market Brief: Tissue-Engineered Wound Care Market Expected To Reach $1.9BN By 2024 Amid Rising Chronic Disease
The skin replacement market is led by three key players who have all been impacted by COVID-19, but the sector may see a quicker rebound than others as treatments cannot be deferred for a long time.